Genmab to access AlgoNomics’ Epibase platform

Ghent, Belgium, May 12, 2005 - AlgoNomics NV announced today it had entered into an agreement granting Genmab A/S access to AlgoNomics’ Epibase® platform for T-cellepitope identification.

According to Dr. Jan van de Winkel, CSO of Genmab, “Epibase® can be used to validate the intrinsically low immunogenicity of our fully human therapeutic antibody leads that are currently in clinical and pre-clinical phases.”

Dr. Ignace Lasters, CEO of AlgoNomics, comments: “We are pleased to be working with Genmab. This important player in the therapeutic antibody field recognizes the value that Epibase® can bring to further optimize as well as expedite its product development cycle”.

The collaboration was entered upon for 3 years. No financial details are disclosed.

About Epibase®
Epibase® is AlgoNomics’ proprietary platform for T-cell epitope identification. This epitope dicovery is applied to vaccine development in the cancer and infectious diseases field, as well as to protein epitope profiling and Immunotuning®.

The uniqueness of Epibase® resides in its capability to identify all T-cell epitopes for any collection of proteins from any biological source (viral, cancer or other), for all HLA types covering most of the human population. The approach allows to document and optimize leads such as vaccines and therapeutic proteins for any specific population.

Unlike learning-based methods, Epibase® can identify epitopes for those HLA sub-types for which little or no experimental data is available. In addition, Epibase® has the intrinsic capacity to identify epitopes sequence patterns that would not be recognized by learning-based tools.

About AlgoNomics
AlgoNomics is a Belgium based biotech company that provides structural bioinformatics services to develop rationally designed therapeutics in the broad field of immunotherapy. AlgoNomics offers in silico support to companies that develop rationally designed vaccines and therapeutic proteins.

AlgoNomics owns a rich, proprietary platform for structure-based protein and peptide design. The technology platform contains biologically validated, innovative tools, which have been developed in-house.

AlgoNomics’ premier product is the Epibase® platform for T-cell epitope identification in different population groups. The company is serving a broad range of customers including Ablynx, Bayer Cropscience, Genmab and J&J Tibotec.
For more information about AlgoNomics visit www.algonomics.com

About Genmab
Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. At present, Genmab has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche and Amgen. A broad alliance provides Genmab with access to Medarex, Inc.'s array of proprietary technologies, including the UltiMAb® platform for the rapid creation and development of human antibodies to virtually any disease target. Genmab is headquartered in Copenhagen, Denmark, and has operations in Utrecht, The Netherlands, and Princeton, New Jersey in the US.
For more information about Genmab, visit: www.genmab.com.
UltiMAb® is a trademark of Medarex, Inc.
Epibase® is a trademark of Algonomics NV

Further information:

AlgoNomics N.V.
ir. Philippe Stas
Chief Operating Officer
Technologiepark 4
B-9052 Gent – Belgium
Tel.: +32.(0)9.241.11.00
Fax.: +32.(0)9.241.11.02
Philippe.Stas@algonomics.com

###

Publisher Contact Information:

AlgoNomics
+32.(0)9.241.11.00
Philippe.Stas@algonomics.com

Company profile of AlgoNomics (acquired by Lonza Group)
Past press releases of AlgoNomics (acquired by Lonza Group).